DARE - Dare Bioscience Inc logo

Dare Bioscience Inc

DARE

Daré Bioscience develops therapies for women's health, including contraception, pelvic pain, and sexual health. Key products are XACIATO for bacterial vaginosis, the hormone-free Ovaprene contraceptive, and various treatments for menopause and HPV.

⚕️ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago →$6today

Score Overview

1 Year
Score
Net Growth18.00%
Net TrendGrew
Net Income Consistency—
Rev Growth32.59%
Rev TrendGrew
Revenue Consistency—
5 Years
Score5.1
Net Growth71.61%
Net Trend60%
Net Income Consistency—
Rev Growth-86.34%
Rev Trend33%
Revenue Consistency—
10 Years
Score
Net Growth72.05%
Net Trend50%
Net Income Consistency
Rev Growth78.32%
Rev Trend25%
Revenue Consistency
All Time
Score
Net Growth52.93%
Net Trend50%
Net Income Consistency
Rev Growth17x
Rev Trend30%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Dare Bioscience Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. DARE does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.65—
1 Year2025-10-22
$ 2.07-68.52%
5 Years2021-10-22
$ 17.64-96.31%
10 Years2016-10-21
$ 113.33-99.42%
All Time2014-04-10
$ 822.00-99.92%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1M-$ 10M$ 12M
2025$ 1M-$ 13M$ 24M
2024-$ 4M$ 15M
2023$ 2M-$ 30M$ 10M
2022$ 10M$ 406M$ 34M
2021$ 10M-$ 38M$ 51M
2020$ 0.00-$ 27M$ 4M
2019$ 0.00-$ 14M$ 4M
2018$ 0.00-$ 16M$ 6M
2017$ 0.00-$ 11M$ 7M
2016$ 766K-$ 39M$ 34M
2015$ 0.00-$ 39M$ 75M
IPO2014$ 80K-$ 23M$ 51M
DARE - Dare Bioscience Inc logo

Dare Bioscience Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 0.00 to $ 1M and net income went from -$ 27M to -$ 13M. Revenue increased in 2 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 0.00 to $ 1M and net income went from -$ 39M to -$ 13M. Revenue increased in 3 of those 10 years; net income in 5.

Dare Bioscience Inc currently holds a 5-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.

Membership

Explore DARE with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies